Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction

Patients with chronic heart failure and a reduced ejection fraction were randomly assigned to the soluble guanylate cyclase stimulator vericiguat or placebo, in addition to guideline-based medical therapy. The incidence of death from cardiovascular causes or first hospitalization for heart failure w...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2020-05, Vol.382 (20), p.1883-1893
Hauptverfasser:	Armstrong, Paul W, Pieske, Burkert, Anstrom, Kevin J, Ezekowitz, Justin, Hernandez, Adrian F, Butler, Javed, Lam, Carolyn S.P, Ponikowski, Piotr, Voors, Adriaan A, Jia, Gang, McNulty, Steven E, Patel, Mahesh J, Roessig, Lothar, Koglin, Joerg, O’Connor, Christopher M
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Binding sites Blood pressure Cardiology and cardiovascular system Cardiovascular Diseases - mortality Chronic Disease Congestive heart failure Death Diuretics Double-Blind Method Ejection fraction Enrollments Female Follow-Up Studies Guanylate cyclase Heart failure Heart Failure - drug therapy Heart Failure - physiopathology Heterocyclic Compounds, 2-Ring - adverse effects Heterocyclic Compounds, 2-Ring - therapeutic use Hospitalization Hospitalization - statistics & numerical data Human health and pathology Humans Hypotension Hypotension - chemically induced Incidence Intravenous administration Life Sciences Male Middle Aged Patient safety Peptides Pyrimidines - adverse effects Pyrimidines - therapeutic use Soluble Guanylyl Cyclase - metabolism Stroke Volume Syncope Syncope - chemically induced Ventricular Dysfunction, Left - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Patients with chronic heart failure and a reduced ejection fraction were randomly assigned to the soluble guanylate cyclase stimulator vericiguat or placebo, in addition to guideline-based medical therapy. The incidence of death from cardiovascular causes or first hospitalization for heart failure was lower among patients who received vericiguat.
ISSN:	0028-4793 1533-4406 1533-4406
DOI:	10.1056/NEJMoa1915928